Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Odonate Therapeutics stock price, quote, forecast and news

ODTC
US6760791060
A2H9FC

Price

17,100.00
Today +/-
+0
Today %
+0 %
P

Odonate Therapeutics stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Odonate Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Odonate Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Odonate Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Odonate Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Odonate Therapeutics Stock Price History

DateOdonate Therapeutics Price
9/18/202417,100.00 undefined
9/16/202417,050.00 undefined

Odonate Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Odonate Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Odonate Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Odonate Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Odonate Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Odonate Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Odonate Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Odonate Therapeutics’s growth potential.

Odonate Therapeutics Revenue, EBIT and net profit per share

DateOdonate Therapeutics RevenueOdonate Therapeutics EBITOdonate Therapeutics Net Income
20200 undefined-127.43 M undefined-126.35 M undefined
20190 undefined-114.93 M undefined-111.83 M undefined
20180 undefined-90.76 M undefined-88.96 M undefined
20170 undefined-32.74 M undefined-32.74 M undefined
20160 undefined-3.09 M undefined-3.09 M undefined
20150 undefined-158,000 undefined-158,000 undefined

Odonate Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201520162017201820192020
000000
------
------
000000
0-3-32-90-114-127
------
0-3-32-88-111-126
--966.67175.0026.1413.51
5.35.35.384.895.536.57
------
Details

Keystats

Revenue and Growth

The Odonate Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Odonate Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020
           
0.142.6198.11139.05180.46157.27
000000
000000
000000
00.274.840.753.472.61
0.142.87202.95139.8183.93159.87
00.010.171.93.246.3
000000
000000
000000
000000
000.380.971.661.71
00.010.552.874.98.01
0.142.88203.49142.67188.83167.89
           
3.577.770.240.240.30.37
01.06235.03252.01402.08502.21
-3.46-6.55-39.29-128.25-240.08-366.43
000000
000000
0.112.28195.98124162.3136.14
0.030.574.310.7815.5814.17
00.033.217.379.212.91
0006600
000000
000000
0.030.67.5118.2124.7827.07
000000
000000
0000.461.754.67
0000.461.754.67
0.030.67.5118.6726.5331.74
0.142.88203.49142.67188.83167.89
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Odonate Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Odonate Therapeutics's financial health and stability.

Assets

Odonate Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Odonate Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Odonate Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Odonate Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020
0-3-32-88-111-126
000000
000000
0011432
01561110
000000
000000
0-1-25-67-96-113
000-100
000-100
000000
000000
000000
042211013890
042211013890
------
000000
02195-5841-23
-0.17-1.73-25.94-69-96.8-113.56
000000

Odonate Therapeutics stock margins

The Odonate Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Odonate Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Odonate Therapeutics.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Odonate Therapeutics's sales revenue. A higher gross margin percentage indicates that the Odonate Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Odonate Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Odonate Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Odonate Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Odonate Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Odonate Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Odonate Therapeutics Margin History

Odonate Therapeutics Gross marginOdonate Therapeutics Profit marginOdonate Therapeutics EBIT marginOdonate Therapeutics Profit margin
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Odonate Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Odonate Therapeutics earnings per share therefore indicates how much revenue Odonate Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Odonate Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Odonate Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Odonate Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Odonate Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Odonate Therapeutics Revenue, EBIT and net profit per share

DateOdonate Therapeutics Sales per ShareOdonate Therapeutics EBIT per shareOdonate Therapeutics Earnings per Share
20200 undefined-19.39 undefined-19.22 undefined
20190 undefined-20.8 undefined-20.24 undefined
20180 undefined-18.55 undefined-18.18 undefined
20170 undefined-6.09 undefined-6.09 undefined
20160 undefined-0.58 undefined-0.58 undefined
20150 undefined-0.03 undefined-0.03 undefined

Odonate Therapeutics business model

Odonate Therapeutics Inc is a biopharmaceutical company that specializes in the development of medications to assist patients with serious illnesses. The company was founded in 2013 by a team of experienced scientists, doctors, and experts from the pharmaceutical industry, with the goal of creating a revolutionary alternative to conventional cancer therapy. The idea was to develop a therapy that minimizes the unwanted effects of chemotherapy and radiation, while still being equally effective in fighting cancer. The business model of Odonate Therapeutics is based on the development of medications that specifically target certain substances in order to achieve maximum effectiveness and efficiency. The company primarily focuses on the research and development of cancer therapeutics and has already brought several innovative products to market, which are currently in the clinical testing phase. One of the main areas of Odonate Therapeutics' research and development is medication based on taxanes. Taxanes are a class of medications known for their effectiveness in fighting cancer. Odonate Therapeutics has the innovative idea of combining these substances with others to minimize the side effects of taxanes. The goal is to create a new generation of medications that offer a targeted approach to fighting cancer. Another focus of Odonate Therapeutics is the development of medications for the treatment of patients with breast cancer. The company has already conducted several testing phases for its flagship product, Odonate Therapeutics' Tesetaxel. Tesetaxel is a novel chemotherapy drug that aims to achieve higher efficacy with lower side effects. The results of the studies have been promising and have the potential to change the lives of patients with breast cancer. Another product developed by Odonate Therapeutics is the medication Odonate Therapeutics' Ladiratuzumab Vedotin. This is a cancer drug that was developed in phase 1 studies and is suitable for the treatment of patients with solid tumors. In this study, it has been shown to be well-tolerated and has shown promising results in fighting cancer cells. Over the past few years, Odonate Therapeutics Inc has achieved an impressive track record by developing innovative medications that have the potential to improve patients' lives. The research and development of cancer therapeutics is an area that requires increasing attention, as cancer remains one of the leading causes of death worldwide. Odonate Therapeutics aims to address this challenge by developing innovative products that meet the needs of patients. Overall, Odonate Therapeutics has quickly established a strong reputation in the biotech industry, and the company appears to be on a good path. The company has many promising medication pipeline programs, and the management team consists of experienced leaders focused on developing therapeutics and improving patients' quality of life. Odonate Therapeutics is one of the most popular companies on Eulerpool.com.

Odonate Therapeutics SWOT Analysis

Strengths

Odonate Therapeutics Inc has a strong pipeline of innovative drugs in development, focusing on the treatment of cancer. This provides them with a competitive advantage in the pharmaceutical industry.

Weaknesses

One identified weakness of Odonate Therapeutics Inc is their heavy reliance on the success of their drug candidates. If any of these candidates fail to meet regulatory requirements or achieve expected results, it could have a significant negative impact on the company's financial performance and reputation.

Opportunities

There is a growing demand for effective and targeted cancer treatments globally, presenting Odonate Therapeutics Inc with significant opportunities for market expansion and revenue growth. Additionally, the company has the potential to form strategic partnerships or collaborations with larger pharmaceutical companies, which could accelerate their drug development process and provide additional resources.

Threats

One of the threats facing Odonate Therapeutics Inc is intense competition within the pharmaceutical industry. This could impact their ability to successfully launch and commercialize their drugs, as competitors with similar products may already have established market presence. Additionally, any changes in government regulations or healthcare policies could also pose a threat to Odonate's operations and financial stability.

Odonate Therapeutics Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Odonate Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Odonate Therapeutics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Odonate Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Odonate Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Odonate Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Odonate Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Odonate Therapeutics Stock splits

In Odonate Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Odonate Therapeutics.

Odonate Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2021-3,369.37 -5,800  (-72.14 %)2021 Q2
3/31/2021-8,248.43 -9,000  (-9.11 %)2021 Q1
12/31/2020-1,596.3 -1,660  (-3.99 %)2020 Q4
9/30/2020-1,940.55 -1,860  (4.15 %)2020 Q3
6/30/2020-1,997.16 -2,180  (-9.16 %)2020 Q2
3/31/2020-2,078.76 -1,980  (4.75 %)2020 Q1
12/31/2019-1.01 -0.9  (10.94 %)2019 Q4
9/30/2019-1.08 -0.88  (18.35 %)2019 Q3
6/30/2019-1.27 -1.15  (9.22 %)2019 Q2
3/31/2019-1.26 -1.16  (8.25 %)2019 Q1
1
2

Eulerpool ESG Scorecard© for the Odonate Therapeutics stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

36

👫 Social

29

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Odonate Therapeutics list of shareholders

%
Name
Stocks
Change
Date
 % Fidelity Management & Research Company LLC1102/29/2024
 % DWS Investments UK Limited0-61/31/2023
 % Bridgeway Capital Management, LLC0-223/31/2023
 % The Vanguard Group, Inc.0-163/31/2023
1

Odonate Therapeutics Executives and Management Board

Mr. Michael Hearne58
Odonate Therapeutics Chief Financial Officer
Compensation 572,171
Mr. Craig Johnson61
Odonate Therapeutics Independent Director
Compensation 274,442
Mr. Robert Rosen66
Odonate Therapeutics Director
Compensation 249,442
Ms. Laura Douglass57
Odonate Therapeutics Independent Director
Compensation 249,442
Mr. Kevin Tang
Odonate Therapeutics Chairman of the Board, Chief Executive Officer (since 2013)
Compensation 1
1
2

Odonate Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,270,650,64---
1

Most common questions regarding Odonate Therapeutics

What values and corporate philosophy does Odonate Therapeutics represent?

Odonate Therapeutics Inc represents values of innovation, dedication, and patient-centric approach in the field of pharmaceuticals. The company is committed to developing and commercializing medicines to improve the lives of patients with cancer. Odonate Therapeutics fosters a corporate philosophy that emphasizes the importance of scientific research, clinical advancement, and collaboration with healthcare professionals. With a focus on oncology, the company strives to bring transformative therapies to patients in need. Odonate Therapeutics Inc seeks to revolutionize cancer treatment through groundbreaking advancements, ensuring hope and improved outcomes for individuals facing this devastating disease.

In which countries and regions is Odonate Therapeutics primarily present?

Odonate Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Odonate Therapeutics achieved?

Odonate Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and gained approval for its lead product, tesetaxel, a chemotherapy drug. Tesetaxel has demonstrated promising results in clinical trials, showcasing its potential as an effective treatment for diverse forms of cancer. Odonate Therapeutics Inc also secured strategic collaborations with renowned institutions and organizations, further enhancing its research and development capabilities. These achievements position Odonate Therapeutics Inc as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes and advancing cancer therapeutics.

What is the history and background of the company Odonate Therapeutics?

Odonate Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for the treatment of cancer. The company was founded in 2013 and is headquartered in San Diego, California. Odonate's main product candidate, tesetaxel, is an oral chemotherapy drug currently in advanced clinical trials for the treatment of various types of cancer, including breast cancer. With a team of experienced professionals and a strong commitment to improving patient outcomes, Odonate Therapeutics Inc. is dedicated to bringing novel cancer therapies to market and making a positive impact in the field of oncology.

Who are the main competitors of Odonate Therapeutics in the market?

The main competitors of Odonate Therapeutics Inc in the market include pharmaceutical companies focused on developing and commercializing oncology treatments, such as Pfizer Inc, Merck & Co., Inc, and Novartis AG. These established players have a strong presence in the oncology market and offer a range of oncology therapeutics. However, Odonate Therapeutics Inc distinguishes itself by providing innovative therapies that specifically target and address unmet medical needs in the treatment of breast cancer.

In which industries is Odonate Therapeutics primarily active?

Odonate Therapeutics Inc is primarily active in the healthcare industry.

What is the business model of Odonate Therapeutics?

The business model of Odonate Therapeutics Inc is focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company is primarily engaged in the research, development, and clinical trials of its proprietary drug candidates, with a specific focus on the treatment of breast cancer. Odonate Therapeutics aims to address unmet medical needs and improve patient outcomes by delivering novel cancer treatments. By leveraging its expertise in oncology drug development, the company aims to create value for stakeholders and contribute to advancing the field of cancer therapeutics.

What is the P/E ratio of Odonate Therapeutics 2024?

The P/E ratio cannot be calculated for Odonate Therapeutics at the moment.

What is the P/S ratio of Odonate Therapeutics 2024?

The P/S cannot be calculated for Odonate Therapeutics currently.

What is the AlleAktien quality score of Odonate Therapeutics?

The AlleAktien quality score for Odonate Therapeutics is 2/10.

What is the revenue of Odonate Therapeutics 2024?

The revenue cannot currently be calculated for Odonate Therapeutics.

How high is the profit of Odonate Therapeutics 2024?

The profit cannot currently be calculated for Odonate Therapeutics.

What is the business model of Odonate Therapeutics

Odonate Therapeutics Inc is a biotechnology company that specializes in developing innovative therapies for cancer. The company focuses on developing drugs that can target and effectively fight cancer cells while being gentle on the patient's healthy tissue. The goal of Odonate Therapeutics is to improve the quality of life and prolong the survival time of cancer patients.

What is the Odonate Therapeutics dividend?

Odonate Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Odonate Therapeutics pay dividends?

The dividend cannot currently be calculated for Odonate Therapeutics or the company does not pay out a dividend.

What is the Odonate Therapeutics ISIN?

The ISIN of Odonate Therapeutics is US6760791060.

What is the Odonate Therapeutics WKN?

The WKN of Odonate Therapeutics is A2H9FC.

What is the Odonate Therapeutics ticker?

The ticker of Odonate Therapeutics is ODTC.

How much dividend does Odonate Therapeutics pay?

Over the past 12 months, Odonate Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Odonate Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Odonate Therapeutics?

The current dividend yield of Odonate Therapeutics is .

When does Odonate Therapeutics pay dividends?

Odonate Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Odonate Therapeutics?

Odonate Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Odonate Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Odonate Therapeutics located?

Odonate Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Odonate Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Odonate Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Odonate Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Odonate Therapeutics in the year 2023?

In the year 2023, Odonate Therapeutics distributed 0 USD as dividends.

In which currency does Odonate Therapeutics pay out the dividend?

The dividends of Odonate Therapeutics are distributed in USD.

All fundamentals about Odonate Therapeutics

Our stock analysis for Odonate Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Odonate Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.